Ritonavir-boosted Lopinavir Monotherapy

• Status: Completed
• Trial end date: 2011-02-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess 48-week treatment responses, tolerability, and steady-state minimum plasma concentrations of ritonavir-boosted lopinavir monotherapy for salvage therapy in HIV-1 infected patients who failed antiretroviral regimens containing NRTI and NNRTI.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bamrasnaradura Infectious Diseases Institute
• Treatments: Lopinavir; Reverse Transcriptase Inhibitors; Ritonavir

Criteria

Inclusion Criteria:

1. HIV-1 infected patients >18 years of age,

2. failed NNRTI-based antiretroviral therapy with M184V, thymidine analogue mutations (TAMs) and NNRTI-associated mutations

3. had plasma HIV-1 RNA >1,000 copies/mL.

Exclusion Criteria:

1. Had a history of exposure to protease inhibitor

2. Receipt a medication that has drug-drug interactions with lopinavir.